Ridaforolimus in advanced or metastatic soft tissue and bone sarcomas

Expert Review of Clinical Pharmacology

Volumn 6, Issue 5, 2013, Pages 465-482

  Mita, monica M ^a   Gong, Jun ^a   Chawla, Sant P ^a  

^a CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

clinical trials; mTOR inhibitor; ridaforolimus; sarcoma; SUCCEED

Indexed keywords

ANTINEOPLASTIC AGENT; MTOR PROTEIN, HUMAN; RAPAMYCIN; RIDAFOROLIMUS; TARGET OF RAPAMYCIN KINASE;

ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; BONE NEOPLASMS; CLINICAL TRIAL (TOPIC); HUMAN; METASTASIS; PATHOLOGY; SARCOMA; SOFT TISSUE NEOPLASMS; TREATMENT OUTCOME; TUMOR INVASION;

ANTINEOPLASTIC AGENTS; BONE NEOPLASMS; CLINICAL TRIALS AS TOPIC; HUMANS; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; SARCOMA; SIROLIMUS; SOFT TISSUE NEOPLASMS; TOR SERINE-THREONINE KINASES; TREATMENT OUTCOME;

EID: 84894270317     PISSN: 17512433     EISSN: 17512441     Source Type: Journal    
DOI: 10.1586/17512433.2013.827397     Document Type: Article

References (84)

1. Ducimetière F, Lurkin A, Ranchère-Vince D et al. Incidence of sarcoma histotypes and molecular subtypes in a prospective epidemiological study with central pathology review and molecular testing. PLoS ONE 6 (8), e20294 (2011).
2. Clark MA, Fisher C, Judson I, Thomas JM. Soft-tissue sarcomas in adults. N. Engl. J. Med. 353, 701–711 (2005).
3. Keedy VL. Treating metastatic soft-tissue or bone sarcomas – potential role of ridaforolimus. Onco. Targets Ther. 5, 153–160 (2012).
4. Purohit S, Bhise R, Appachu S, Lakshmaiah KC, Govindbabu K. Systemic therapy in soft tissue sarcomas: past, present, and future. Indian J. Surg. Oncol. 2 (4), 327–331 (2011).
5. Riedel RF. Systemic therapy for advanced soft tissue sarcomas. Cancer 118, 1474–1485 (2012).
6. van Oosterom AT, Mouridsen HT, Nielsen OS et al. Results of randomised studies of the EORTC Soft Tissue and Bone Sarcoma Group (STBSG) with two different ifosfamide regimens in first- and second-line chemotherapy in advanced soft tissue sarcoma patients. Eur. J. Cancer 38, 2397–2406 (2002).
7. Garcia del Muro X, Lopez-Pousa A, Martin J et al. A phase II trial of temozolomide as a 6-week, continuous, oral schedule in patients with advanced soft tissue sarcoma: a study by the Spanish Group for Research on Sarcomas. Cancer 104, 1706–1712 (2005).
8. Moore M, Desai J. New drugs in the management of sarcoma. Cancer Forum 34 (3), 140–146 (2010).
9. van der Graaf WTA, Gelderblom H. New systemic therapy options for advanced sarcomas. Curr. Treat. Options Oncol. 13, 306–317 (2012).
10. Schöffski P, Ray-Coquard IL, Cioffi A et al. Activity of eribulin mesylate in patients with soft-tissue sarcoma: a phase 2 study in four independent histological subtypes. Lancet Oncol. 12, 1045–1052 (2011).
11. Edmonson JH, Ryan LM, Blum RH et al. Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas. J. Clin. Oncol. 11, 1269–1275 (1993).
12. Santoro A, Tursz T, Mouridsen H et al. Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. J. Clin. Oncol. 13, 1537–1545 (1995).
13. Casali PG. Histology- and non-histology-driven therapy for treatment of soft tissue sarcomas. Ann. Oncol. 23 (Suppl. 10), x167 – x169 (2012).
14. Dileo P, Morgan JA, Zahrieh D et al. Gemcitabine and vinorelbine combination chemotherapy for patients with advanced soft tissue sarcomas: results of a phase II trial. Cancer 109, 1863–1869 (2007).
15. Antman K, Crowley J, Balcerzak SP et al. An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas. J. Clin. Oncol. 11, 1276–1285 (1993).
16. Maki RG, Wathen JK, Patel SR et al. Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002. J. Clin. Oncol. 25, 2755–2763 (2007).
17. Silk AW, Schuetze SM. Histology-specific therapy for advanced soft tissue sarcoma and benign connective tissue tumors. Curr. Treat. Options Oncol. 13, 285–298 (2012).
18. Judson I. Targeted therapies in soft tissue sarcomas. Ann. Oncol. 22 (Suppl. 7), vii277–280 (2010).
19. Riedel RF. Targeted agents for sarcoma: is individualized therapy possible in such a diverse tumor type? Semin. Oncol. 38 (5), (Suppl. 3), S30 – S42 (2011).
20. Riedel RF, Maki RG, Wagner AJ. Targeted therapy in sarcoma: should we be lumpers or splitters? ASCO Meeting Library 652–657 (2012).
21. Blay JY. Updating progress in sarcoma therapy with mTOR inhibitors. Ann. Oncol. 22, 280–287 (2011).
22. Mahalingam D, Sankhala K, Mita A, Giles F, Mita MM. Targeting the mTOR pathway using deforolimus in cancer therapy. Future Oncol. 5 (3), 291–303 (2009).
23. Vilar E, Perez-Garcia J, Tabernero J. Pushing the envelope in the mTOR pathway. The second generation of inhibitors. Mol. Cancer Ther. 10 (3), 395–403 (2011).
24. Mita M, Sankhala K, Abdel-Karim I, Mita A, Giles F. Deforolimus (AP23573) a novel mTOR inhibitor in clinical development. Expert Opin. Investig. Drugs 17 (12), 1947–1954 (2008).
25. Liu Q, Thoreen C, Wang J, Sabatini D, Gray NS. mTOR mediated anti-cancer drug discovery. Drug Discov. Today Ther. Strateg. 6 (2), 47–55 (2009).
26. Yuan R, Kay A, Berg WJ, Lebwohl, D. Targeting tumorigenesis: development and use of mTOR inhibitors in cancer therapy. J. Hematol. Oncol. 2 (45), 1–12 (2009).
27. Vézina C, Kudelski A, Seghal SN. Rapamycin (AY-22,989), a new antifungal antiobiotic I. Taxonomy of the producing streptomycete and isolation of the active principle. J. Antibiot. (Tokyo) 28 (10), 721–726 (1975).
28. Faivre S, Kroemer G, Raymond E. Current development of mTOR inhibitors as anticancer agents. Nat. Rev. Drug Discov. 5, 671–688 (2006).
29. Agulnik M. New developments in mammalian target of rapamycin inhibitors for the treatment of sarcomas. Cancer 118, 1486–1497 (2012).
30. Merimsky O, Bernstein-Molho R, Sagi-Eisenberg R. Targeting the mammalian target of rapamycin in myxoid chondrosarcoma. Anticancer Drugs 19, 1019–1021 (2008).
31. Wagner AJ, Malinowska-Kolodziej I, Morgan JA et al. Clinical activity of mTOR inhibition with sirolimus in malignant perivascular epithelioid cell tumors: targeting the pathogenic activation of mTORC1 in tumors. J. Clin. Oncol. 28, 835–840 (2010).
32. Bernstein-Molho R, Kollender Y, Issakov J et al. Clinical activity of mTOR inhibition in combination with cyclophosphamide in the treatment of recurrent unresectable chondrosarcomas. Cancer Chemother. Pharmacol. 70, 855–860 (2012).
33. Wolff N, Kabbani W, Bradley T, Raj G, Watumull L, Brugarolas J. Sirolimus and temsirolimus for epithelioid angiomyolipoma. J. Clin. Oncol. 28, e65 – e68 (2010).
34. Schuetze SM, Baker LH, Maki RG. Sirolimus reduced tumor-related morbidity and resulted in biochemical and radiographic response in patients with progressive sarcoma. J. Clin. Oncol. (Abstract) 24, 9503 (2006).
35. Houghton PJ, Morton CL, Kolb EA et al. Initial testing (stage 1) of the mTOR inhibitor rapamycin by the pediatric preclinical testing program. Pediatr. Blood Cancer 50, 799–805 (2008).
36. Houghton PJ, Morton CL, Gorlick R et al. Stage 2 combination testing of rapamycin with cytotoxic agents by the Pediatric Preclinical Testing Program. Mol. Cancer Ther. 9, 101–112 (2010).
37. Jimeno A, Rudek MA, Kulesza P et al. Pharmacodynamic-guided modified continuous reassessment method-based, dose-finding study of rapamycin in adult patients with solid tumors. J. Clin. Oncol. 26, 4172–4179 (2008).
38. Cohen EE, Sharma M, Janisch LA et al. A phase I study of sirolimus and bevacizumab in patients with advanced malignancies. Eur. J. Cancer 47 (10) (2011).
39. Italiano A, Kind M, Stoeckle E, Jones N, Coindre JM, Bui B. Temsirolimus in advanced leiomyosarcomas: patterns of response and correlation with the activation of the mammalian target of rapamycin pathway. Anticancer Drugs 22 (5), 463–467 (2011).
40. Italiano A, Delcambre C, Hostein I et al. Treatment with the mTOR inhibitor temsirolimus in patients with malignant PEComa. Ann. Oncol. 21, 1135–1137 (2010).
41. Raymond E, Alexandre J, Faivre S et al. Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer. J. Clin. Oncol. 22, 2336–2347 (2004).
42. Hidalgo M, Buckner JC, Erlichman C et al. A phase I and pharmacokinetic study of temsirolimus (CCI-779) administered intravenously daily for 5 days every 2 weeks to patients with advanced cancer. Clin. Cancer Res. 12, 5755–5763 (2006).
43. Buckner JC, Forouzesh B, Erlichman C et al. Phase I, pharmacokinetic study of temsirolimus administered orally to patients with advanced cancer. Invest. New Drugs 28, 334–342 (2010).
44. Naing A, LoRusso P, Fu S et al. Insulin growth factor-receptor (IGF-1R) antibody cixutumumab combined with the mTOR inhibitor temsirolimus in patients with refractory Ewing's sarcoma family tumors. Clin. Cancer Res. 18 (9), 2625–2631 (2012).
45. Okuno S, Bailey H, Mahoney MR et al. A phase 2 study of temsirolimus (CCI-779) in patients with soft tissue sarcomas: a study of the Mayo Phase 2 Consortium (P2C). Cancer 117 (15), 3468–3475 (2011).
46. Geoerger B, Kieran MW, Grupp S et al. Phase II study of temsirolimus in children with high-grade glioma, neuroblastoma, and rhabdomyosarcoma. Eur. J. Cancer 48 (2), 253–262 (2012).
47. Shitara K, Yatabe Y, Mizota A, Sano T, Nimura Y, Muro K. Dramatic tumor response to everolimus for malignant epithelioid angiomyolipoma. Jpn J. Clin. Oncol. 41, 814–816 (2011).
48. Rossi F, Ehlers I, Agosti V et al. Oncogenic Kit signaling and therapeutic intervention in a mouse model of gastrointestinal stromal tumor. Proc. Natl Acad. Sci. USA 103: 12843–12848 (2006).
49. Hernando E, Charytonowicz E, Dudas ME et al. The AKT-mTOR pathway plays a critical role in the development of leiomyosarcomas. Nat. Med. 13, 748–753 (2007).
50. O'Donnell A, Faivre S, Burris HA III et al. Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors. J. Clin. Oncol. 26, 1588–1595 (2008).
51. Tabernero J, Rojo F, Calvo E et al. Dose- and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: a phase I tumor pharmacodynamic study in patients with advanced solid tumors. J. Clin. Oncol. 26, 1603–1610 (2008).
52. Fouladi M, Laningham F, Wu J et al. Phase I study of everolimus in pediatric patients with refractory solid tumors. J. Clin. Oncol. 25, 4806–4812 (2007).
53. Quek R, Wang Q, Morgan JA et al. Combination mTOR and IGF-1R inhibition: phase I trial of everolimus and figitumumab in patients with advanced sarcomas and other solid tumors. Clin. Cancer Res. 17 (4), 871–879 (2011).
54. Richter S, Pink D, Hohenberger P et al. Multicenter, triple-arm, single-stage, phase II trial to determine the efficacy and safety of everolimus (RAD001) in patients with refractory bone or soft tissue sarcomas including GIST. J. Clin. Oncol. (Abstract) 28 (Suppl. 15), 10038 (2010).
55. Schoffski P, Reichardt P, Blay JY et al. A phase I-II study of everolimus (RAD001) in combination with imatinib in patients with imatinib-resistant gastrointestinal stromal tumors. Ann. Oncol. 21, 1990–1998 (2010).
56. Rivera VM, Squillace RM, Miller D et al. Ridaforolimus (AP23573; MK-8669), a potent mTOR inhibitor, has broad antitumor activity and can be optimally administered using intermittent dosing regimens. Mol. Cancer Ther. 10, 1059–1071 (2011).
57. Squillace RM, Miller D, Cookson M et al. Antitumor activity of ridaforolimus and potential cell-cycle determinants of sensitivity in sarcoma and endometrial cancer models. Mol. Cancer Ther. 10, 1959–1968 (2011).
58. Mita MM, Rowinsky EK, Goldston ML et al. Phase I, pharmacokinetic (PK), and pharmacodynamic (PD) study of AP23573, an mTOR inhibitor, administered IV daily X 5 every other week in patients (pts) with refractory or advanced malignancies. J. Clin. Oncol. (Abstract) 22 (Suppl. 14), 3076 (2004).
59. Desai AA, Janisch L, Berk LR et al. A phase I trial of a novel mTOR inhibitor AP23573 administered weekly (wkly) in patients (pts) with refractory or advanced malignancies: a pharmacokinetic (PK) and pharmacodynamic (PD) analysis. J. Clin. Oncol. (Abstract) 22 (Suppl. 14), 3150 (2004).
60. Mita MM, Mita AC, Chu QS et al. Phase I trial of the novel mammalian target of rapamycin inhibitor deforolimus (AP23573; MK-8669) administered intravenously daily for 5 days every 2 weeks to patients with advanced malignancies. J. Clin. Oncol. 26, 361–367 (2008).
61. Hartford CM, Desai AA, Janisch L et al. A phase I trial to determine the safety, tolerability, and maximum tolerated dose of deforolimus in patients with advanced malignancies. Clin. Cancer Res. 15, 1428–1434 (2009).
62. Berk L, Mita MM, Kreisberg J et al. Analysis of the pharmacodynamic activity of the mTOR inhibitor ridaforolimus (AP23573, MK-8669) in a phase 1 clinical trial. Cancer Chemother. Pharmacol. 69, 1369–1377 (2012).
63. Fetterly GJ, Mita MM, Britten CD et al. Pharmacokinetics of oral deforolimus (AP23573, MK-8669). J. Clin. Oncol. (Abstract) 26 (Suppl. 15), 14555 (2008).
64. Seki Y, Yamamoto N, Tamura Y et al. Phase I study for ridaforolimus, an oral mTOR inhibitor, in Japanese patients with advanced solid tumors. Cancer Chemother. Pharmacol. 69, 1099–1105 (2012).
65. Gore L, Trippett TM, Katzenstein HM et al. A multicenter, first-in-pediatrics phase I study of ridaforolimus (AP23573, MK-8669) in patients (pts) with refractory solid tumors. J. Clin. Oncol. (Abstract) 28 (Suppl. 15), 9531 (2010).
66. Stroh M, Palcza J, McCrea J et al. The effect of multiple doses of rifampin and ketoconazole on the single-dose pharmacokinetics of ridaforolimus. Cancer Chemother. Pharmacol. 69, 1247–1253 (2012).
67. Stroh M, Li X, Marsilio S et al. The minimal impact of food on the pharmacokinetics of ridaforolimus. Cancer Chemother. Pharmacol. 70, 177–182 (2012).
68. Mita MM, Poplin E, Britten CD et al. Phase I/IIa trial of the mammalian target of rapamycin inhibitor ridaforolimus (AP23573; MK-8669) administered orally in patients with refractory or advanced malignancies and sarcoma. Ann. Oncol. 24, 1104–1111 (2013).
69. Perotti A, Locatelli A, Sessa C et al. Phase IB study of the mTOR inhibitor ridaforolimus with capecitabine. J. Clin. Oncol. 28 (30), 4554–4561 (2010).
70. Cessa C, Tosi D, Viganò L et al. Phase Ib study of weekly mammalian target of rapamycin inhibitor ridaforolimus (AP23573; MK-8669) with weekly paclitaxel. Ann. Oncol. 21, 1315–1322 (2010).
71. Di Cosimo, Bendell JC, Cervantes-Ruiperez A et al. A phase I study of the oral mTOR inhibitor ridaforolimus (RIDA) in combination with the IGF-1R antibody dalotozumab (DALO) in patients (pts) with advanced solid tumors. J. Clin. Oncol. (Abstract) 28 (Suppl. 15), 3008 (2010).
72. Chawla SP, Staddon AP, Baker LH et al. A phase 2 study of the mTOR inhibitor ridaforolimus (AP23573; MK 8669) in patients with advanced bone and soft tissue sarcomas. J. Clin. Oncol. 30 (1), 78–84 (2012).
73. Blay JY, Chawla SP, Ray-Coquard I et al. Phase III, placebo-controlled trial (SUCCEED) evaluating ridaforolimus as maintenance therapy in advanced sarcoma patients following clinical benefit from prior standard cytotoxic chemotherapy: long-term (≥24 months) overall survival results. J. Clin. Oncol. (Abstract) 30 (Suppl. 15), 10010 (2012).
74. van Glabbeke M, Verweij J, Judson I et al. Progression-free rate as the principal end-point for phase II trials in soft-tissue sarcomas. Eur. J. Cancer 38, 543–549 (2002).
75. Martins F, Augusto de Oliveira M, Wang Q et al. A review of oral toxicity associated with mTOR inhibitor therapy in cancer patients. Oral. Oncol. (2013) (In press).
76. Michaelis LC, Ratain MJ. Measuring response in a post-RECIST world: from black and white to shades of grey. Nat. Rev. Cancer 6, 409–414 (2006).
77. Darling JA. Different view of sarcoma statistics (2009). http://sarcomahelp.org/sarcoma_statistics.html (Accessed 29 March 2013)
78. US National Institute of Health. NCI SEER Cancer Statistics (2009). http://seer.cancer.gov/statistics/ (Accessed 29 March 2013)
79. ® is first in over a decade approved by FDA to prevent organ rejection in adult liver transplant patients (2013). www.novartis.com/newsroom/media-releases/en/2013/1678805.shtml (Accessed 29 March 2013)
80. Merck. ARIAD announces full enrollment in phase 3 Succeed trial evaluating ridaforolimus in patients with metastatic sarcomas (2009). www.merck.com/licensing/news-and-events/ariad-press-release.html (Accessed 29 March 2013)
81. Merck and ARIAD announce European Medicines Agency accepts marketing authorization application for ridaforolimus, investigational mTOR inhibitor (2011). www.merck.com/licensing/news-and-events/Ariad4-press-release.html (Accessed 29 March 2013)
82. Merck. FDA accepts new drug application filing for ridaforolimus, investigational mTOR inhibitor (2011). www.mercknewsroom.com/press-release/research-development-news/fda-accepts-new-drug-application-filing-ridaforolimus-invest (Accessed 29 March 2013)
83. Merck. Merck receives complete response letter from U.S. Food and Drug Administration for investigational medicine ridaforolimus (2012). www.mercknewsroom.com/press-release/research-and-development-news/merck-receives-complete-response-letter-us-food-and-drug (Accessed 29 March 2013)
84. Merck. Merck provides update on EU Marketing Authorization Application for ridaforolimus (2012). www.mercknewsroom.com/press-release/research-and-development-news/merck-provides-update-eu-marketing-authorization-applica (Accessed 29 March 2013)